about
KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab.Morphological and immunohistochemical study of ovarian and tubal dysplasia associated with tamoxifenBRCA1 induces major energetic metabolism reprogramming in breast cancer cells.Activation of EGFR, HER2 and HER3 by neurotensin/neurotensin receptor 1 renders breast tumors aggressive yet highly responsive to lapatinib and metformin in mice.Early telomere shortening and genomic instability in tubo-ovarian preneoplastic lesions.ERCC1 and telomere status in breast tumours treated with neoadjuvant chemotherapy and their association with patient prognosisTargeting DNA repair by coDbait enhances melanoma targeted radionuclide therapyComparison of the prognostic significance of Chevallier and Sataloff's pathologic classifications after neoadjuvant chemotherapy of operable breast cancer.Rare EGFR exon 18 and exon 20 mutations in non-small-cell lung cancer on 10 117 patients: a multicentre observational study by the French ERMETIC-IFCT network.Panitumumab combined with irinotecan for patients with KRAS wild-type metastatic colorectal cancer refractory to standard chemotherapy: a GERCOR efficacy, tolerance, and translational molecular study.[¹²³I]ICF01012 melanoma imaging and [¹³¹I]ICF01012 dosimetry allow adapted internal targeted radiotherapy in preclinical melanoma models.Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer.A multicenter blinded study evaluating EGFR and KRAS mutation testing methods in the clinical non-small cell lung cancer setting--IFCT/ERMETIC2 Project Part 1: Comparison of testing methods in 20 French molecular genetic National Cancer Institute plAnti-melanoma efficacy of internal radionuclide therapy in relation to melanin target distribution.Targeted radionuclide therapy of melanoma: anti-tumoural efficacy studies of a new 131I labelled potential agent.Natural antisense transcripts of HIF-1alpha are conserved in rodents.Prospective, multicenter French study evaluating the clinical impact of the Breast Cancer Intrinsic Subtype-Prosigna® Test in the management of early-stage breast cancers.Increase in morphine antinociceptive activity by a P-glycoprotein inhibitor in cisplatin-induced neuropathy.[Diagnostic approach for breast cancer classification].TERT promoter status and gene copy number gains: effect on TERT expression and association with prognosis in breast cancer.Induction chemotherapy for breast carcinoma: predictive markers and relation with outcome.Comment regarding Bergmann et al.'s "Assessment of the in vitro and in vivo properties of a 99mTc-labeled inhibitor of the multidrug resistant gene product of P-glycoprotein".[The Fallopian tube odyssey: from the ovary to the tube. About high-grade serous ovarian carcinoma].Changes and predictive and prognostic value of the mitotic index, Ki-67, cyclin D1, and cyclo-oxygenase-2 in 710 operable breast cancer patients treated with neoadjuvant chemotherapy.Vincristine-induced neuropathy in the rat is not modified by drug-drug interactions with the P-glycoprotein inhibitor verapamil.Involvement of the multidrug resistance transporters in cisplatin-induced neuropathy in rats. Comparison with the chronic constriction injury model and monoarthritic rats.Leukocyte's Hif-1 expression and training-induced erythropoietic response in swimmers.In vivo efficacy of melanoma internal radionuclide therapy with a 131I-labelled melanin-targeting heteroarylcarboxamide molecule.[Strategy for molecular testing in pulmonary carcinoma].Multicentric neoadjuvant pilot Phase II study of cetuximab combined with docetaxel in operable triple negative breast cancer.O(6)-methylguanine-DNA methyl transferase gene expression and prognosis in breast carcinoma.Complete Response to Aflibercept-FOLFIRI in One Patient With Colorectal Cancer Refractory to Bevacizumab-FOLFOX: A Possible Autocrine Vascular Endothelial Growth Factor Receptor 2-Related Mechanism.Change in HER2 (ERBB2) gene status after taxane-based chemotherapy for breast cancer: polyploidization can lead to diagnostic pitfalls with potential impact for clinical management.Multicentric neoadjuvant phase II study of panitumumab combined with an anthracycline/taxane-based chemotherapy in operable triple-negative breast cancer: identification of biologically defined signatures predicting treatment impactMorphological and immunohistochemical pattern of tubo-ovarian dysplasia and serous tubal intraepithelial carcinomaIn vitro detection of the MDR phenotype in rat myocardium: use of PCR, [3H]daunomycin and MDR reversing agentsComparison between technetium-99m-sestamibi and hydrogen-3-daunomycin myocardial cellular retention in vitroPgp immunochemistry: use with caution: correspondence re: C-H. Kao et al., P-glycoprotein and multidrug resistance-related protein expressions in relation to technetium-99m methoxyisobutylisonitrile scintimammography findings. Cancer Res., 61: 1412-Single static view 99mTc-sestamibi scintimammography predicts response to neoadjuvant chemotherapy and is related to MDR expression[Place of anatomopathology in evaluation of response to neoadjuvant chemotherapy. Prognostic and predictive markers: example of breast cancer]
P50
Q27851422-9B363A42-CDE6-463F-B8C3-7CFE21EF1D64Q33851264-F45E87D9-0BEF-418C-B952-4B9816A9A254Q33882790-E78C4C1D-FAA1-4637-8387-2E49A1D8571BQ34483533-241EC8B4-4526-4AE5-AE2B-AFF599225A1FQ34669840-7089801A-95AC-4227-A963-E27921E63C84Q36175526-6588D5D7-3CEC-4A9C-A2E8-0549B8AF20D4Q37022343-2D54CB8B-840E-428B-BF5A-FD49B3EA9850Q37189169-BE03BD53-9CE8-48D7-8606-E01A694F2842Q37404105-06BEA492-B0F1-40F1-871F-B9E540FC2F8CQ38463163-CAD71428-09B9-471C-8A4B-3026C53BE7C2Q38924577-93978BE4-DDDA-49B1-ADFF-E1E79A4CC55AQ38934630-26558BB0-03D1-4898-AC30-0BA3EEE2DE74Q39067796-A079D4B0-540F-419B-8711-193B82675824Q39707461-326E10EE-972C-4EA7-9B40-C685E3E08115Q39852328-C547CDF9-531D-4C66-A6D3-80C0CE2ADE07Q40516322-F7042DD2-975E-4F9C-9CEB-86E82AA98924Q42517033-F8372BCC-4E6F-43F8-8EAC-5EB68618199CQ43280401-5CBBB821-45A3-41D2-9C33-3F65BFD6FC0EQ43846576-C4850E0E-EDFB-41BD-A169-6DDFD737C728Q44378342-5F90C462-33DF-4DCF-B1C9-0F436B2851E7Q44435364-8415DB19-816C-4387-A1AD-168EC4F592FFQ44454372-10142C7A-3A2C-4949-BD06-D56E99AC43F4Q45888929-BB9DF040-C192-44D1-BA7A-4C5C8084F7FBQ46192906-FCCA5FD7-93A9-4DF2-AF32-0BDF8FC4B217Q46421437-A0E1998F-E3A0-474F-823E-3A96B2B9CEB0Q48465770-14545DCF-BB9F-42D4-BCD0-2F50E81DC2D0Q50725968-D44BC2F8-C9A5-47D7-99D5-AAA69D52322EQ53120428-C0E17A08-5F32-41AB-8330-BE7C77E5D02BQ53205948-96E12792-132C-4474-9003-7ABDBB3B80B5Q53805931-D576F6C7-4045-4664-9747-389319607C29Q53956474-B18B32F6-0623-4B7A-BDE0-1899753ECB5AQ54175821-0FD9FC89-3465-464F-9D39-C6F37703F688Q54457679-F1D5EBD5-9F59-444A-9301-593C3D672320Q57579477-18851AB2-80ED-4254-9D7B-006BC417295AQ64390213-1231D5D6-6533-4195-86FA-6E5CCF2EF8F5Q71963301-9DE10DF2-038E-4165-8E95-04C0CBF7204FQ73889513-2AAE51C9-EAAF-4EA1-9F5E-C3930E71C710Q77542485-ECE92AC8-C28D-4A86-BA8D-7B3896D67313Q77949966-0AEF0E11-8BEA-421E-BDC9-DE65C23820BFQ80007797-D3884177-2062-45FB-9650-0AF46EC5A892
P50
description
researcher
@en
name
A Cayre
@en
A Cayre
@nl
type
label
A Cayre
@en
A Cayre
@nl
prefLabel
A Cayre
@en
A Cayre
@nl
P106
P31
P496
0000-0002-2578-8557